Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group, 2-part Study Investigating the Effect of LIK066 on Body Weight in Dysglycemic (Prediabetes or Type 2 Diabetes) and Normoglycemic Patients With Elevated Body Mass Index
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Licogliflozin (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 26 Jun 2018 Results from this and 2 more srudies, presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 12 Apr 2016 Status changed from recruiting to completed.
- 22 Feb 2016 Treatment arms changed from 3 to 6 as reported by ClinicalTrials.gov record.